Sensitivity and specificity of CT colonography for the detection of colonic neoplasia after positive faecal occult blood testing: Systematic review and meta-analysis by Plumb, AA et al.
Plumb, AA; Halligan, S; Pendsé, DA; Taylor, SA; Mallett, S; (2014) Sensitivity and specificity 
of CT colonography for the detection of colonic neoplasia after positive faecal occult blood 
testing: Systematic review and meta-analysis. European Radiology, 24 (5) 1049 - 1058. 
10.1007/s00330-014-3106-0 
 
Article 
 
Sensitivity and specificity of CTC for the detection of colonic 
neoplasia after positive fecal occult blood testing: Systematic 
review and meta-analysis 
 
Abstract 
 
Objective: CT colonography (CTC) is recommended after positive fecal occult blood testing 
(FOBt) when colonoscopy is incomplete or infeasible. We aimed to estimate the sensitivity 
and specificity of CTC for colorectal cancer and adenomatous polyps following positive FOBt 
via systematic review. 
 
Methods: The MEDLINE, EMBASE, AMED and Cochrane Library databases were searched 
for CTC studies reporting sensitivity and specificity for colorectal cancer and adenomatous 
polyps. Included subjects had tested FOBt-positive by guaiac or immunochemical methods. 
Per-patient detection rates were summarized via forest plots. Meta-analysis of sensitivity 
and specificity was conducted using a bivariate random effects model and the average 
operating point calculated. 
 
Results: Of 538 articles considered, 5 met inclusion criteria, describing results from 622 
patients. Research study quality was good. CTC had a high per-patient average sensitivity of 
88.8% (95%CI 83.6 to 92.5%) for ≥6mm adenomas or colorectal cancer, with low between-
study heterogeneity. Specificity was both more heterogeneous and lower, at an average of 
75.4% (95%CI 58.6 to 86.8%).  
 
Conclusion: Few studies have investigated CTC in FOBt-positive individuals. CTC is 
sensitive at a ≥6mm threshold but specificity is lower and variable. Despite the limited data, 
these results suggest CTC may adequately substitute for colonoscopy when the latter is 
undesirable. 
 
Keywords CT colonography, Colorectal Neoplasms, Screening, Occult blood, Review, 
Systematic 
 
Key points 
 
 Faecal occult blood testing is the commonest mass-screening test for colorectal 
cancer. 
 Few studies specifically evaluate CT colonography after positive faecal occult blood 
testing. 
 CTC is approximately 89% sensitive for ≥6mm adenomas/cancer in this setting. 
 Specificity is lower, at approximately 75%, and more variable. 
 CT colonography is a good alternative when colonoscopy is undesirable. 
 
Abbreviations 
 
CAD = computer assisted detection 
CTC = computed tomographic colonography 
CRC = colorectal cancer 
gFOBt = guaiac faecal occult blood test 
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FIT = faecal immunochemical test 
NPV = negative predictive value 
PPV = positive predictive value 
QUADAS-2 = quality assessment of diagnostic accuracy studies, second revision 
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Introduction 
 
Worldwide, over half a million people die from colorectal cancer (CRC)[1] annually. 
Population screening reduces mortality in two ways: Established malignancy is detected 
sooner, facilitating cure; and precursor polyps (namely adenomas) can be removed, 
preventing cancer development subsequently. Internationally, most screening programmes 
use faecal occult blood testing[2], which is proven in meta-analysis of randomised trials to 
reduce CRC-related mortality[3]. Faecal testing (whether by guaiac-based techniques, 
gFOBt, or immunochemical techniques, FIT) is widely available[4], acceptable to 
screenees[5] and cost-effective[6]. 
 
Merely demonstrating occult blood loss cannot improve outcomes unless cancer is found 
and treated, or large adenomas removed. For most, colonoscopy both confirms cancer and 
permits endoluminal excision of smaller adenomas and cancers. However, colonoscopy may 
be incomplete, contraindicated or refused by some screenees[7]. To maximize neoplasia 
detection, an alternative test is required. One possibility is CT colonography (CTC), which 
has been recommended when colonoscopy is not feasible or incomplete[8]. This 
recommendation is largely based on meta-analysis of cohort studies[9–11] and two 
randomised trials of symptomatic older patients[12, 13]. Whilst extrapolation from such 
literature is intuitively logical, gFOBt/FIT-positive screenees have such a high prevalence of 
abnormality that subsequent tests require extremely high sensitivity to achieve an 
acceptable negative predictive value. Additionally, screen-detected cancers are earlier stage 
than symptomatic tumours[14], and could be more difficult to detect at CTC. Furthermore, 
advanced histologic features are more common in gFOBt/FIT-positives, even at equivalent 
adenoma diameter[15, 16]. Since CTC has less sensitivity for small polyps[10, 17], this 
implies more advanced neoplasia will be missed when testing gFOBt/FIT-positive subjects 
than asymptomatic individuals, in whom subcentimetre adenomas rarely harbour advanced 
neoplasia[18]. 
 
If CTC is to be adopted widely following positive gFOBt/FIT, sensitivity and specificity for 
cancer and adenomas should be known with precision. The relevant comparator is 
colonoscopy, since it is accurate, widely available and generally safe[7]. Without this 
information, clinicians and patients are unable to balance the risks of colonoscopy against 
the chance of missing neoplasia with CTC. To address this, we performed a systematic 
review and meta-analysis of the sensitivity and specificity of CTC for colorectal cancer and 
adenomatous polyps in gFOBt/FIT-positive individuals. 
 
Materials and Methods 
 
Data sources 
 
A literature search of the MEDLINE database was performed using Pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed). All primary studies for the period January 1994 (the 
year CT colonography was first described) to February 2013 were considered. To retrieve 
articles relevant to stool testing, the Medical Subject Headings (MeSH) terms feces, Occult 
Blood and Immunologic Tests were combined with the free-text terms faeces, feces, faecal, 
fecal, FIT, iFOB*, FOB* and occult. This search was combined with a search for CTC-related 
literature using the MeSH terms colonography, colography, CT colonography, CT 
colonoscopy, CT pneumocolon, virtual colonoscopy or virtual endoscopy and the free text 
terms colonography, colography, CTC, computerized tomographic colonoscopy, computed 
tomographic colonoscopy and CT pneumocolon. Subsequently, the Cochrane library, 
EMBASE, AMED and OVID were searched using the free text terms fec*, face*, FOB*, 
gFOB*, iFOB*, FIT, immunochem* and immunolog* combined with CT comput* tomogra*, 
colonogra*, virtua* colonosc* and virtua* endosc*. Reference lists from reports eventually 
selected were also searched manually. 
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Study selection 
 
Studies were eligible if the patient population had tested positive for faecal occult blood and 
been imaged by CTC (defined below). Studies describing other populations were potentially 
eligible if separate per-patient data were presented for gFOBt/FIT-positive participants. Only 
full reports of original data from in vivo research in human subjects were considered. Review 
articles, editorials, commentaries, book chapters, abstracts, guidelines and position 
statements were ineligible.  
 
 
Target disorder 
 
To be included, the focus of the study had to be the detection of colorectal neoplasia using 
CTC in comparison with a reference test. Studies assessing a technical development (for 
example, computer-assisted detection, CAD) or alteration in CTC technique were potentially 
eligible if results were presented for CTC examinations conducted according to consensus 
standards[19].  
 
CT test methods 
 
On the basis of consensus documents for the performance of CTC[19, 20], all patients had 
to undergo bowel preparation (either cleansing, tagging or both) prior to imaging in a 
minimum of two positions, with or without intravenous contrast. Interpretation of CTC before 
the reference test (or blinding of the observer to reference test findings) was required. No 
stipulation was made regarding the mode of interpretation used by CTC observers, nor 
regarding the use of CAD. 
 
Reference test 
 
All CTC findings had to be verified by a reference test. Conventional colonoscopy, 
segmental unblinded colonoscopy and surgery (with subsequent histopathology) were 
acceptable alternatives.  
 
Data extraction 
 
All abstracts of primary studies were independently screened by two authors (AAP and DAP) 
who excluded clearly ineligible studies. The full text of potentially eligible studies was 
retrieved and scrutinised. Differences in opinion regarding eligibility were resolved in face-to-
face consensus. From each eligible study, the following were extracted; (a) publication year, 
(b) number and age range of gFOBt/FIT-positive subjects, (c) single- or multi-centre study 
design, (d) CTC technique (reconstruction interval, use of cathartics, stool tagging, 
intravenous contrast medium and the approximate radiation dose), (e) approximate 
experience of CTC readers, (f) interpretation strategy (including two-dimensional or three-
dimensional viewing, use of CAD, and double-reporting), (g) reference standard against 
which CTC and colonoscopy were compared, (h) number of patients with cancer by the 
reference standard, (i) per-patient sensitivity of CTC for cancer, (j) per-patient sensitivity of 
colonoscopy for cancer, (k) number of patients with ≥10mm and ≥6mm polyps and 
adenomas, including advanced adenomas, by the reference standard, (l) per-patient 
sensitivity of CTC for ≥10mm and ≥6mm polyps, adenomas and advanced adenomas, (m) 
per-patient sensitivity of colonoscopy for ≥10mm and ≥6mm polyps, adenomas and 
advanced adenomas, (n) specificity of CTC for polyps, adenomas and advanced adenomas 
(at ≥10mm and ≥6mm thresholds) and (o) positive and negative predictive values of CTC for 
cancers, polyps, adenomas and advanced adenomas at ≥6mm and ≥10mm thresholds. 
Specificity of CTC for cancers cannot be calculated because large polyps and cancers are 
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only distinguishable post-hoc (i.e. histologically). Article quality was judged using QUADAS-2 
(quality assessment tool of diagnostic accuracy studies)[21].  
 
Analysis 
 
Numbers of included and excluded studies (and reasons for exclusion), patient 
characteristics, study design, CTC technique, observer experience and viewing mode were 
tabulated and analysed with descriptive statistics. The QUADAS-2 assessment was 
converted into a summary score of either “high risk”, “low risk” or “unclear”, for both the risk 
of bias and concern over applicability to the systematic review question, as recommended 
by the QUADAS-2 authors[21]. 
 
Per-patient 2x2 contingency tables were constructed for meta-analysis of sensitivity and 
specificity. Forest plots of sensitivity and specificity were generated using the forest 
command of the metafor package[22] for R version 2.15.1[23]. Heterogeneity between 
primary studies was assessed using the I2 statistic, with values of 25%, 50% and 75% taken 
to indicate low, moderate and high heterogeneity respectively. Meta-analysis of paired 
sensitivity and specificity was conducted via a bivariate random effects model that enables 
estimation of a summary receiver operating characteristic curve using the R package mada. 
The results for single-reader CTC were used, since this is the most frequent mode of 
interpretation in current clinical practice. Bivariate models allow for possible correlation 
between sensitivity and specificity[24, 25]. The following factors that might increase 
heterogeneity were considered as moderator covariates in the bivariate model: (a) year of 
publication; (b) number of included participants; (c) prevalence of 6-9mm and ≥10mm 
adenomas or carcinoma; (d) single- or multi-centre design; (e) use of faecal tagging; (f) 
reader experience; and (g) use of three-dimensional interpretation. Covariates (a), (b) and 
(c) were treated as continuous variables, and (d) to (g) as binary variables. 
 
Results 
Search results 
 
A flow diagram of abstracts examined and articles retrieved, included and excluded (with 
reasons) is shown in Figure 1. In summary, 122 studies were identified from the Pubmed 
and Cochrane Library search and 416 from the EMBASE, AMED and OVID search. 39 full-
text articles were screened and ultimately 5 were included. Excluded studies are detailed in 
the Appendix. 
 
Characteristics of included studies 
 
Five articles were included, reporting four distinct studies[26–30]. Two of these articles 
reported different primary outcome measures for the same patient cohort[26, 27]. All four 
studies were performed in Europe: One in the Netherlands[26, 27], one in Italy[29], one in 
France[30] and one international study in Italy and Belgium[28]. The Italian study was from a 
single centre, the Netherlands study used two centres, the French study used 26 centres 
and the international study used 21 centres initially, although only 12 contributed patients to 
the final analysis. The two articles reporting the same patient group were both included (as 
relevant data were presented across the two articles) but individual subjects were not 
duplicated during analysis. 
 
Patient characteristics and CTC technique 
 
A total of 622 gFOBt/FIT-positive patients were enrolled in the selected studies, ranging from 
49 to 302 per study (Table 1). Two studies were designed specifically to assess gFOBt/FIT-
positive patients[26, 27, 29] whereas the other two included gFOBt-positive patients as a 
subgroup of other high-risk populations[28, 30]. Only the results of gFOBt/FIT-positive 
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subjects are included here. The age range was 50 to 75 years (one study reported mean 
and interquartile range[30]). Prevalence of ≥6mm adenomas or cancer ranged from 32.0 to 
65.3%. Cathartic bowel preparation was used by all except Liedenbaum et al, who used a 
reduced-laxative regime. Faecal tagging was used variably (see Table). All studies used 
dual patient positioning, multislice CT, low dose (<100mAs), unenhanced acquisition and 
narrow reconstruction intervals. Reading strategy was left to radiologist preference in two 
studies[28, 30] and primary 2D in the other two[26, 27, 29]. Computer-aided detection (CAD) 
was not used. Liedenbaum et al reported results for both single- and double-reporting[26]. A 
minimum level of radiologist experience was required by all studies, ranging from 50 to 100 
cases. The reference standard was universally segmental unblinded colonoscopy (i.e. initial 
colonoscopy optimised by re-examination following revelation of CTC findings).  
 
Study quality 
 
Overall research study quality was good. In one study, 10 patients were excluded because 
CTC images were judged non-diagnostic and a further 2 had incomplete colonoscopy[26, 
27]. In clinical practice, a variable proportion of patients will have poor quality CTC and it is 
not possible to simply exclude them. However, such cases were a small proportion of the 
total number in this particular study (12 exclusions, 302 participants), implying a negligible 
effect on overall results. In another report, patient flow through the study was not reported 
separately for gFOBt-positive participants[30]. All studies used segmental unblinded 
colonoscopy as the reference standard, a practice which theoretically may lead to 
incorporation bias. The summary QUADAS-2 results are presented in Table 2. 
 
Sensitivity and negative predictive value 
 
Two studies [27, 29] reported the sensitivity of CTC for colorectal cancer separately from the 
sensitivity for adenomas. Sensitivity for CRC was 100% in one study[29] (2 of 2 cancers 
detected) and 95.5% in the other (21 of 22 cancers detected)[27]. The two studies 
describing CTC for high risk patients[28, 30] (including some gFOBt/FIT-positives) did not 
report sensitivity for cancer in the gFOBt/FIT-positive subset. Initial colonoscopy did not miss 
any cancers (vs unblinded colonoscopy) in the included studies.  
 
Regarding sensitivity for adenomas, the four studies used slightly different outcome 
measures; nonetheless, heterogeneity between studies was low (I2 = 0.0%). Regge et al[28] 
reported per-patient sensitivity for advanced adenomas or cancer measuring ≥6mm, with 
CTC detecting 96 of 111 such patients (86.5%). No data were presented at a ≥10mm 
threshold. Liedenbaum et al[27] reported a 91% per-patient sensitivity of double-reported 
CTC for ≥6mm lesions (of any histology), with 192 of 211 such patients being detected by 
CTC. Unusually for the CTC literature, this article used a size cut-off before CTC was termed 
a true-positive: For example, a 4mm polyp reported at CTC which was ultimately measured 
as 6mm by the reference standard was regarded as a CTC false-negative, since a CTC 
finding of a 4mm polyp would not typically provoke colonoscopy. In the corresponding report 
of the same patients[26], a more conventional polyp-matching algorithm was used and 
results were presented for both double-reported and single-reader CTC. The mean 
sensitivity of double-reported CTC for ≥6mm adenomas or carcinoma was 93% versus 89% 
for a single radiologist. Corresponding sensitivities for ≥10mm adenomas or carcinomas 
were 95% and 92% for double- and single-reporting respectively. Heresbach et al[30] 
described per-patient sensitivity at ≥6mm and ≥10mm thresholds. CTC was 88% sensitive at 
the 6mm threshold (correctly finding 14 of 16 patients) and 92% sensitive at the 10mm 
threshold (12 of 13 patients), for both polyps and adenomas. Finally, Sali et al[29] reported 
per-patient sensitivity for cancer or adenomas measuring ≥6mm, correctly identifying 21 of 
22 patients (95.5%). No per-patient data were presented at a ≥10mm threshold. These data 
are summarised in table 3 and the forest plot in figure 2.  
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Only one study reported the per-patient sensitivity of colonoscopy for adenomas in 
comparison to the segmental unblinded reference standard in gFOBt/FIT-positives: 
Liedenbaum et al[26] found a 98% sensitivity for adenomas or carcinomas ≥6mm and a 99% 
sensitivity at a ≥10mm threshold. Heresbach et al[30] reported a per-patient sensitivity for 
colonoscopy of 99.5% and 99.7% for ≥6mm and ≥10mm polyps respectively, although did 
not stratify by gFOBt status. Regge et al[28] found that blinded colonoscopy only missed two 
advanced adenomas (measuring 13 and 18mm), although whether or not these patients 
were gFOBt-positive was not stated. 
 
Specificity and positive predictive value 
 
Overall, specificity varied substantially between studies, ranging from 52% to 91% at a 
≥6mm threshold. Consequently, heterogeneity was high (I2 = 78.3%), summarised in Table 4 
and the forest plot in figure 2. Since different radiologists in different studies may vary the 
point at which they judge a test positive, sensitivity and specificity may vary simply because 
of the arbitrary threshold used by an individual radiologist. Furthermore, there may be 
differences in the spectrum of cases or sizes of polyps across the studies. A bivariate model 
was used to construct a summary ROC curve of the included studies (figure 3), taking this 
into account. None of the moderator covariates (year of publication, number of included 
participants, prevalence of abnormality, single- or multi-centre design, use of faecal tagging, 
reader experience or use of three-dimensional interpretation) were found to be significant, 
perhaps due to the small number of primary studies. From this model, the operating point 
has average sensitivity of 88.8% (95%CI 83.6 to 92.5%) and specificity of 75.4% (95%CI 
58.6 to 86.8%) with the summary curve being reasonably close to the top left corner of ROC 
space. 
 
Discussion 
 
CTC is a relatively novel technology that has matured and is now widely available[31]. It is 
replacing the barium enema for radiological evaluation of the colon, since randomised trials 
show it is more sensitive and misses fewer cancers and large polyps in older symptomatic 
adults[12]. The English Bowel Cancer Screening Programme recommends CTC for gFOBt-
positive patients who are unsuitable for colonoscopy[8]. However, it is striking how little 
evidence exists regarding the diagnostic accuracy of CTC in gFOBt/FIT-positive patients. 
Only four studies have investigated this group, with only two having gFOBT/FIT-positive 
subjects as their direct focus. National policies are therefore governed largely by 
extrapolation from these small cohort studies and related reports of higher-risk patient 
groups. 
 
Nonetheless, the estimated sensitivity of 88.8% (and range of 86-96% for the component 
studies) for adenomas or cancer ≥6mm suggests that CTC is sufficiently sensitive to 
substitute for colonoscopy when necessary. Furthermore, heterogeneity was low, implying 
the (limited) available literature is consistent. This very high sensitivity is greater than that 
reported in prior meta-analyses of CTC, which range from 69%[17] to 86%[10] for ≥6mm 
polyps. We suspect this is due to increased average lesion size in our meta-analysis as a 
consequence of pre-selection by gFOBt/FIT (which preferentially detects larger polyps and 
cancers via their propensity to bleed). For example, patients with ≥1cm 
adenomas/carcinomas heavily outnumbered those with 6-9mm neoplasms in our meta-
analysis (246 versus 100), whereas this pattern was reversed in a prior, unrestricted meta-
analysis[10]. Since CTC is more sensitive for these large lesions, their relative over-
representation inevitably increases the pooled estimate of CTC sensitivity. Although based 
on small numbers, pooled sensitivity for cancer was 96% (95%CI 79.8-99.8%), identical to 
that derived from a broader meta-analysis of the diagnostic accuracy of CTC[9]. Notably, the 
sensitivity of colonoscopy for cancer (judged against segmental unblinded colonoscopy) was 
95% in that meta-analysis, implying the two tests have very similar sensitivity for established 
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malignancy. Sensitivity for cancer is particularly important since a common reason for 
performing CTC over colonoscopy is co-morbidity. Detection of smaller adenomas is less 
crucial, particularly those lacking advanced features. The estimated progression rate of even 
histologically advanced adenomas to carcinoma is approximately 3-4% per annum[32], 
implying that the small chance of missing an advanced adenoma may be acceptable. 
 
Specificity and PPV were less good, with the latter ranging from 62 to 88%, somewhat lower 
than the 92-93% reported when CTC is used for asymptomatic screenees[33, 34]. The 
pooled estimate of specificity was 75.4%, although heterogeneity was high. Low specificities 
may partly reflect the high prevalence of abnormality in the gFOBt/FIT positive population, 
potentially leading radiologists to report equivocal findings as positive (to maximise 
sensitivity). Furthermore, the minimum level of radiologist experience (50 to 100 cases) was 
substantially lower than the studies reporting high PPV (minimum 300 cases)[33, 34]. 
Additionally, faecal tagging was not used in the study with the lowest specificity[29], which 
reported that most of the false-positives were due to faecal residue. Conversely, Regge et 
al[28] found that most false-positives were due to hyperplastic or diminutive polyps. 
Irrespective, the implication is that CTC may direct a substantial proportion of normal 
patients to colonoscopy. 
 
Since the randomised trials supporting gFOBt population screening employed colonoscopy 
to investigate a positive faecal test result, large-scale screening programmes follow a similar 
model. CTC is commonly used when colonoscopy is incomplete or contraindicated 
(including screenee refusal). Patients included in our meta-analysis were, by definition, able 
to undergo both CTC and colonoscopy. These data are therefore most applicable to a 
patient population deemed fit for colonoscopy i.e. those with an incomplete colonoscopy or 
who refuse it for reasons unrelated to their general health. Conversely, the sensitivity of CTC 
in frailer individuals with relative contraindications to colonoscopy is unknown. Observational 
data show that cancer and adenoma detection rates by CTC in gFOBt-positives are 
substantially lower than corresponding detection rates by colonoscopy[35]. However, these 
screenees were imaged with CTC because colonoscopy was judged inappropriate, meaning 
that this difference may arise from selection bias rather than reduced sensitivity of CTC. 
Nonetheless, the high sensitivity and moderate specificity of CTC found in our systematic 
review may not generalise to frailer patients.  
 
Our review focused on sensitivity and specificity, and did not consider other factors such as 
safety, patient acceptability or cost. Furthermore, the impact on overall screening 
compliance by introducing an additional step in the diagnostic pathway (i.e. faecal testing, 
then CTC, then colonoscopy) is unknown. The high prevalence of abnormality after positive 
gFOBt/FIT suggested to the authors of one component study[27] that universal adoption of 
CTC as a “triage test” would not be cost-effective. Conversely, a recent cost analysis 
concluded that savings would arise via avoiding unnecessary colonoscopy by CTC 
triage[36]. 
The major limitation of this study is the small number of studies available in the primary 
literature for review and meta-analysis. Whilst this is unavoidable, it does imply that our 
estimates of heterogeneity may be inaccurate, and that the summary estimates may be 
substantially affected by a single outlying study. It is therefore reassuring that the two largest 
studies we included[26–28] had almost identical sensitivity and specificity. Additionally, such 
a small number of component studies precludes meaningful assessment of publication bias 
via funnel plots or alternatives, meaning that the result of the meta-analysis should be 
treated with appropriate caution. Assessment of moderator covariates in the bivariate model 
is also potentially limited by the small number of studies, meaning we may have erroneously 
discounted these factors as affecting sensitivity or specificity. 
 
In summary, by systematic review we conclude that few studies have directly addressed 
investigation of gFOBt/FIT-positive populations by CTC. Nonetheless, available studies 
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suggest that the sensitivity of CTC for ≥6mm adenomas or cancer following a positive 
gFOBt/FIT result is 88.8% (95%CI 83.6-92.5%). Specificity is more variable between studies 
and the summary estimate is lower, at 75.4% (95%CI 58.6-86.8%). Our review suggests that 
CTC may adequately substitute for colonoscopy when the latter is undesirable or 
incomplete. The high rate of subsequent testing (predicated by high prevalence of 
abnormality) and relatively reduced sensitivity of CTC compared to colonoscopy suggests 
the latter should remain the preferred test where feasible.  
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Table legends 
 
Table 1:  
Characteristics of the included studies. RI = reconstruction interval, CAD = computer-
assisted detection. *Regge et al reported results for histologically advanced 
adenomas.  
 
Table 2:  
QUADAS-2 quality assessment of the included studies 
 
Table 3:  
Per-patient sensitivity (95% confidence intervals) and negative predictive value (95% 
CI) of CTC. Sn=sensitivity, NR=not reported, NPV=negative predictive value. Data 
from the Liedenbaum et al studies is for single-reader CTC.  
 
Table 4: 
Per-patient specificity (95% confidence intervals) and PPV (95% CI) of CTC. 
Sp=specificity, NR=not reported, PPV=positive predictive value. Data for the 
Liedenbaum et al studies is for single-reader CTC. 
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Figure legends 
 
Figure 1 
Flowchart of the systematic review. 
 
Figure 2 
Forest plot of included studies showing individual and pooled estimates of sensitivity 
and specificity of CTC for ≥6mm adenomas and cancers (Regge et al reported 
histologically advanced neoplasia). For each study, marker area is proportional to 
precision, with greater precision indicated by larger area. Pooled values are derived 
from the bivariate random effects model. TP = true positive, FN = false negative, TN 
= true negative, FP = false positive. 
 
Figure 3 
Summary ROC curve of included studies. The sensitivity of each individual study for 
6mm adenomas or cancer is plotted against 1-specificity. Regge et al (square) 
reported advanced adenomas only. Data for Liedenbaum et al (circle) are for single 
reader CTC. Heresbach et al and Sali et al are represented by a triangle and 
diamond respectively. Grey lines show 95% confidence regions of each individual 
study. Black circle shows the overall estimate at the operating point. 
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Appendix 
 
Studies excluded from the systematic review after full-text reviewed 
 
Author Year Reason for exclusion 
Fenlon 1999 FOBt-positive patients not reported separately 
Pescatore 2000 FOBt-positive patients not reported separately 
Yee 2000 FOBt-positive patients not reported separately 
Laghi 2002 FOBt-positive patients not reported separately 
Laghi 2002 FOBt-positive patients not reported separately 
Macari 2002 FOBt-positive patients not reported separately 
Wong 2002 FOBt-positive patients not reported separately 
Iannaconne 2003 FOBt-positive patients not reported separately 
Iannaconne 2003 FOBt-positive patients not reported separately 
Pineau 2003 FOBt-positive patients not reported separately 
Yee 2003 FOBt-positive patients not reported separately 
Cohnon 2004 FOBt-positive patients not reported separately 
Cotton 2004 FOBt-positive patients not reported separately 
Hoppe 2004 FOBt-positive patients not reported separately 
Iannaconne 2004 FOBt-positive patients not reported separately 
Iannaconne 2005 FOBt-positive patients not reported separately 
Rockey 2005 FOBt-positive patients not reported separately 
Haykir 2006 FOBt-positive patients not reported separately 
Reuterskiold 2006 FOBt-positive patients not reported separately 
Selcuk 2006 FOBt-positive patients not reported separately 
Carrascosa 2007 FOBt-positive patients not reported separately 
Walleser 2007 FOBt-positive patients not reported separately 
Roberts-Thomson 2008 FOBt-positive patients not reported separately 
Sali 2008 Only some patients underwent the reference test 
Fisichella 2009 FOBt-positive patients not reported separately 
Nagata 2009 FOBt-positive patients not reported separately 
Neri 2009 Only some patients underwent the reference test 
Ozsunar 2009 FOBt-positive patients not reported separately 
Sali 2013 Only some patients underwent the reference test 
 
 
 
